



WD GP #1645
Box se Q

Patent Docket P1055R1

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of
Ashkenazi et al.

Serial No.: 09/291,925

Filed: 14 April 1999

For: PROTEIN SECRETION

Group Art Unit: 1645

Examiner: R. Zeman

#8a 8/1/00
T. Gray

CERTIFICATE OF MAILING
I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Assistant Commissioner of Patents, Washington, D.C. 20231 on

July 21, 2000

Janet Tse

Janet Tse

Response to Notice to Comply with Requirements for Patent Applications Containing Nucleotide/Amino Acid Sequence Disclosures

Assistant Commissioner of Patents
Washington, D.C. 20231

RECEIVED

JUL 31 2000

Sir:

TECH CENTER 1600/2900

In response to the Notice to Comply with Requirements for Sequence Disclosures mailed June 21, 2000, consideration of the application in view of the following amendments is respectfully requested. Applicant submits herewith i) substitute paper copy of the Sequence Listing; ii) substitute computer readable form copy of the Sequence Listing and iii) Certificate under 37 CFR §1.825(a) and (b).

IN THE SPECIFICATION

Please replace the Sequence Listing as originally filed (pages 1-3) with the attached Substitute Sequence Listing (pages 1-3).

REMARKS

Applicants request replacement of the existing Sequence Listing with the attached substitute Sequence Listing in response

RECEIVED

TECH CENTER 1600/2900

A

09/291,925



page 2

to the notice to comply with the requirements of 37 C.F.R. 1.821-1.825. No new matter is added by these amendments and their entry is respectfully requested.

Respectfully submitted,
GENENTECH, INC.

Date: July 21, 2000

By: 

Jeffrey S. Kubinec
Reg. No. 36,575

1 DNA Way
So. San Francisco, CA 94080-4990
Phone: (650) 225-8228
Fax: (650) 952-9881



Application No.:09/291925

**NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING
NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES**

The nucleotide and/or amino acid sequence disclosure contained in this application does not comply with the requirements for such a disclosure as set forth in 37 C.F.R. 1.821 - 1.825 for the following reason(s)

- 1. This application clearly fails to comply with the requirements of 37 C.F.R. 1.821-1.825. Applicant's attention is directed to these regulations, published at 1114 OG 29, May 15, 1990 and at 55 FR 18230, May 1, 1990.
- 2. This application does not contain, as a separate part of the disclosure on paper copy, a "Sequence Listing" as required by 37 C.F.R. 1.821(c).
- 3. A copy of the "Sequence Listing" in computer readable form has not been submitted as required by 37 C.F.R. 1.821(e).
- 4. A copy of the "Sequence Listing" in computer readable form has been submitted. However, the content of the computer readable form does not comply with the requirements of 37 C.F.R. 1.822 and/or 1.823, as indicated on the attached copy of the marked -up "Raw Sequence Listing."
- 5. The computer readable form that has been filed with this application has been found to be damaged and/or unreadable as indicated on the attached CRF Diskette Problem Report. A Substitute computer readable form must be submitted as required by 37 C.F.R. 1.825(d).
- 6. The paper copy of the "Sequence Listing" is not the same as the computer readable from ~~as per~~ "Sequence Listing" as required by 37 C.F.R. 1.821(e).
- 7. Other: _____

RECEIVED

JUL 31 2000

TECH CENTER 1600/2900

Applicant Must Provide:

- An initial or substitute computer readable form (CRF) copy of the "Sequence Listing".
- An initial or substitute paper copy of the "Sequence Listing", as well as an amendment directing its entry into the specification.
- A statement that the content of the paper and computer readable copies are the same and, where applicable, include no new matter, as required by 37 C.F.R. 1.821(e) or 1.821(f) or 1.821(g) or 1.825(b) or 1.825(d).

For questions regarding compliance to these requirements, please contact:

For Rules Interpretation, call (703) 308-4216

For CRF Submission Help, call (703) 308-4212

For PatentIn software help, call (703) 308-6856

PLEASE RETURN A COPY OF THIS NOTICE WITH YOUR RESPONSE


RECEIVED
TECH CENTER 1600/2900

A



Patent Docket P1055R1

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of Ashkenazi et al. Serial No.: 09/291,925 Filed: 14 April 1999 For: PROTEIN SECRETION	Group Art Unit: 1645 Examiner: R. Zeman
<p style="text-align: center;">CERTIFICATE OF MAILING I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Assistant Commissioner of Patents, Washington, D.C. 20231 on</p> <p style="text-align: right;">July 21, 2000</p> <p style="text-align: right;"> Janet Tse</p>	

CERTIFICATE RE: SEQUENCE LISTING
RESPONSE UNDER 37 CFR § 1.825(a) and (b)

BOX SEQUENCE
Assistant Commissioner of Patents
Washington, D.C. 20231


Sir:

I hereby state that the amendments, made in accordance with 37 CFR 1.825(a), included in the substitute sheets of the Sequence Listing are supported in the application, as filed, at at least page 5. I hereby state that the substitute sheets of the Sequence Listing do not include new matter.

I further state that the substitute copy of the computer readable form, submitted in accordance with 37 CFR 1.825(b), is the same as the amended Sequence Listing.

Respectfully submitted,

GENENTECH, INC.

Date: July 21, 2000
By: 
Jeffrey S. Rubinec
Reg. No. 36,575

1 DNA Way
So. San Francisco, CA 94080-4990
Phone: (650) 225-8228
Fax: (650) 952-9881